List of Excipients in API sofosbuvir, velpatasvir, and voxilaprevir
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing sofosbuvir, velpatasvir, and voxilaprevir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Gilead Sciences Inc | VOSEVI | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 | ACETONE | 2037-12-01 |
| Gilead Sciences Inc | VOSEVI | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 | ALCOHOL | 2037-12-01 |
| Gilead Sciences Inc | VOSEVI | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 | CELLULOSE, MICROCRYSTALLINE | 2037-12-01 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for sofosbuvir, velpatasvir, and voxilaprevir
Excipient focus: ACETONE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing ACETONE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing ACETONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ALCOHOL
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
sofosbuvir, velpatasvir, and voxilaprevir drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Gilead Sciences Inc | sofosbuvir, velpatasvir, and voxilaprevir | 61958-2401 |
| >Company | >Ingredient | >NDC |
sofosbuvir, velpatasvir, and voxilaprevir drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
